您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

Non-clinical Research-used
Medicine Sample Provider
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 法国药房
产地国家: 法国
所属类别: 心血管系统药物->心血管扩张
处方药:处方药
包装规格: 8毫克 90片/盒
计价单位:
  点击放大  
生产厂家英文名:
MYLAN LABORATORIES
该药品相关信息网址1:
https://www.bcbdexther.fr/BcbDextherWeb/monographie/get?idProduit=31821&p=rO0ABXNyACBmci5yZXNpcC5zZXJ2aWNlcy5vYmplY3RzLktFWVVybAAAAAAAMJXBAgAESQAJaWRQcm9kdWl0SQAEbW9kZUwAAmNldAASTGphdmEvbGFuZy9TdHJpbmc7TAACc2VxAH4AAXhwAAB8TQAAAAJ0ABFSRVNJUC1ERVhUSEVSLVdFQ
原产地英文商品名:
Serc 8mg 90tablets/bottle
原产地英文药品名:
betahistine
中文参考商品译名:
Serc 8毫克 90片/盒
中文参考药品译名:
倍他司汀
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Cerebral arteriosclerosis
英文适应病症2:
Ischemic cerebral Control disease
英文适应病症3:
Orthostatic dizziness
英文适应病症4:
Tinnitus
临床试验期:
完成
中文适应病症参考翻译1:
脑动脉硬化
中文适应病症参考翻译2:
缺血性脑血管病
中文适应病症参考翻译3:
直立性眩晕
中文适应病症参考翻译4:
耳鸣
药品信息:

倍他司汀Betahistine
别名
倍他胺;倍他组啶;甲胺乙比啶;抗眩啶;敏使朗;培他啶
适应症
临床用于内耳眩晕症;对脑动脉硬化、缺血性脑血管病、头部外伤或高血压所致直立性眩晕、耳鸣等亦可用。
注意事项
1.偶有口干、胃部不适、心悸、皮肤瘙痒等不良反应。 2.消化性溃疡、支气管哮喘及嗜铬细胞瘤病人慎用。 3.不可同时用抗组胺药物。

Betahistine
Betahistine hydrochloride is the generic name for the anti vertigo drug SERC. It was first registered in Europe in 1970 for the treatment of Ménière's disease. It is commonly prescribed for people who have balance disorders or to alleviate the vertigo symptoms associated with Ménière's disease.
Betahistine is available in 8 mg, 16 mg, or 24 mg tablets. It is contraindicated for people with peptic ulcers or tumours of the adrenal gland. People with bronchial asthma should be closely monitored.
Recent Updates
A new use may be in the field of obesity management. Dr Nir Barak, of the Rabin Medical Centre in Tel Aviv has undertaken trials[3] and it is reported (Telegraph, UK, 19 February 2007) that volunteers lost more than 1.5 kg/week over twelve weeks and experienced a distaste for fatty foods.
A recent Phase II clinical trial of the new drug in the U.S. suggests that women under the age of 50 who took Histalean (Betahistine) for 12 weeks lost 7 times the weight of those taking a placebo. What's most important to the researchers involved is that none of the 281 patients, males and females aged 18-65, complained of any serious side effects. The recent results were based on a double-blind, placebo-controlled study on people with a Body Mass Index ranging from 30 to 40. (A BMI of 30 and above indicate obesity.) The study was conducted at 19 investigation sites across the U.S. over a 12 week treatment period. The subgroup of high-dose Histalean (Betahistine)-treated women lost an average of 2.91% of their weight versus placebo group which lost only 0.4 %.[4]
Chemistry
Betahistine chemically is 2-[2-(methylamino)ethyl]pyridine, and is formulated as the dihydrochloride salt. Its structure closely resembles that of phenethylamine and histamine.
Pharmacology
Betahistine comes in tablet form and is taken orally. It is rapidly and completely absorbed. The mean plasma half-life is 3-4 hours, and excretion is virtually complete in the urine within 24 hours. Plasma protein binding is very low. Betahistine is transformed into aminoethylpyridine and hydroxyethylpyridine and excreted with the urine as pyridylacetic acid. There is some evidence that one of these metabolites, aminoethylpyridine, may be active and exert effects similar to those of betahistine on ampullar receptors.[5]
Mode of action
Betahistine has a very strong affinity for histamine H3 receptors and a weak affinity for histamine H1 receptors. Betahistine seems to dilate the blood vessels within the middle ear which can relieve pressure from excess fluid and act on the smooth muscle.
The mode of action of betahistine was believed to be a direct stimulating (agonistic) effect on H1 receptors located on blood vessels in the inner ear. This would give rise to local vasodilation and increased permeability, which would help reverse the underlying problem of endolymphatic hydrops.
In addition, betahistine has a powerful antagonistic effects at H3 receptors, and increases the levels of neurotransmitters released from the nerve endings. This is thought to have two consequences;
• the increased amounts of histamine released from histaminergic nerve endings can stimulate H1 receptors, thus augmenting the direct agonistic effects of betahistine on these receptors. This explains the potent vasodilatory effects of betahistine in the inner ear, which are well documented.
• it is postulated that betahistine increases the levels of neurotransmitters such as serotonin in the brainstem, which inhibits the activity of vestibular nuclei. Means, betahistine reduce the firing rate of vestibular nuclei in the brain.
Side effects
• Low level of gastric side effects
• No significant antidopaminergic effects
• Nausea can be a side effect, but the patient is generally already experiencing nausea due to the vertigo so it goes largely unnoticed.

 

于2020-02-24更新

更新日期: 2020-02-04
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15900659515@163.com